MX381069B - Profármacos de carbidopa y l-dopa y métodos de uso. - Google Patents

Profármacos de carbidopa y l-dopa y métodos de uso.

Info

Publication number
MX381069B
MX381069B MX2017005236A MX2017005236A MX381069B MX 381069 B MX381069 B MX 381069B MX 2017005236 A MX2017005236 A MX 2017005236A MX 2017005236 A MX2017005236 A MX 2017005236A MX 381069 B MX381069 B MX 381069B
Authority
MX
Mexico
Prior art keywords
carbidopa
disease
treat parkinson
dopa
prodrug
Prior art date
Application number
MX2017005236A
Other languages
English (en)
Spanish (es)
Other versions
MX2017005236A (es
Inventor
Alexander D Huters
Benoit Cardinal-David
Brian P Enright
Christopher P Miller
Eric A Voight
Geoff G Zhang
James Stambuli
Kassibla E Dempah
Mark A Matulenko
Peter T Mayer
Philip R Kym
Raimundo Ho
Rodger F Henry
Russell C Klix
Scott W Krabbe
Sean E Mackey
Valentino J Stella
Vincent S Chan
Xiaochun Lou
Yanbin Lao
Ye Huang
Zhi Wang
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX381069(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2017005236A publication Critical patent/MX2017005236A/es
Publication of MX381069B publication Critical patent/MX381069B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2017005236A 2014-10-21 2015-10-21 Profármacos de carbidopa y l-dopa y métodos de uso. MX381069B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (2)

Publication Number Publication Date
MX2017005236A MX2017005236A (es) 2017-07-26
MX381069B true MX381069B (es) 2025-03-12

Family

ID=54478240

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003840A MX393568B (es) 2014-10-21 2015-10-21 Profarmacos de carbidopa y l-dopa y metodos de uso
MX2017005236A MX381069B (es) 2014-10-21 2015-10-21 Profármacos de carbidopa y l-dopa y métodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021003840A MX393568B (es) 2014-10-21 2015-10-21 Profarmacos de carbidopa y l-dopa y metodos de uso

Country Status (37)

Country Link
US (7) US9446059B2 (enExample)
EP (3) EP3569587A1 (enExample)
JP (6) JP6567049B2 (enExample)
KR (3) KR20240113982A (enExample)
CN (4) CN111454290B (enExample)
AR (1) AR102389A1 (enExample)
AU (4) AU2015335941B2 (enExample)
BR (1) BR112017008198B1 (enExample)
CA (1) CA2965379A1 (enExample)
CY (2) CY1121826T1 (enExample)
DK (1) DK3209302T3 (enExample)
ES (1) ES2739536T3 (enExample)
FI (1) FIC20230014I1 (enExample)
FR (1) FR23C1035I2 (enExample)
HR (1) HRP20191285T1 (enExample)
HU (2) HUE044115T2 (enExample)
IL (3) IL251829B (enExample)
LT (2) LT3209302T (enExample)
LU (1) LUC00304I2 (enExample)
MX (2) MX393568B (enExample)
MY (1) MY189519A (enExample)
NL (1) NL301224I2 (enExample)
NO (1) NO2023013I1 (enExample)
PH (1) PH12017500746B1 (enExample)
PL (1) PL3209302T3 (enExample)
PT (1) PT3209302T (enExample)
RS (1) RS58972B1 (enExample)
RU (2) RU2743347C2 (enExample)
SA (1) SA521421115B1 (enExample)
SG (1) SG11201703170RA (enExample)
SI (1) SI3209302T1 (enExample)
SM (1) SMT201900376T1 (enExample)
TR (1) TR201908296T4 (enExample)
TW (2) TWI718999B (enExample)
UA (1) UA120437C2 (enExample)
WO (1) WO2016065019A1 (enExample)
ZA (1) ZA201702760B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016011837A (es) 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
SI3209302T1 (sl) 2014-10-21 2019-06-28 Abb Vie Inc. Predzdravila karbidope in L-dope in njihova uporaba za zdravljenje parkinsonove bolezni
US20190224220A1 (en) * 2016-04-20 2019-07-25 Abbvie Inc. Carbidopa and L-Dopa Prodrugs and Methods of Use
US11148999B2 (en) 2016-06-22 2021-10-19 MedChem Partners, LLC Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
CN112770734B (zh) 2018-09-13 2024-08-20 堪培拉大学 抑制方法
US12251365B2 (en) 2018-11-15 2025-03-18 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113677675B (zh) 2019-05-21 2024-07-26 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
JP7696829B2 (ja) 2019-05-21 2025-06-23 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ
CN113727979B (zh) 2019-05-21 2024-09-20 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN119707810A (zh) 2019-05-21 2025-03-28 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ATE118216T1 (de) * 1989-04-20 1995-02-15 Zambon Spa Dopamin-medikament-vorstufe.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
WO1999024442A1 (en) * 1997-11-12 1999-05-20 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
JPWO2004000863A1 (ja) 2002-06-20 2005-10-20 日本水産株式会社 プロドラッグ、その医薬としての使用、およびその製法
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
JP5160786B2 (ja) 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
WO2005041925A2 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
AU2005252220B2 (en) * 2004-06-04 2011-06-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
WO2006014282A2 (en) 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors
DK1959948T3 (da) * 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
AU2007259256A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and L-DOPA
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
BRPI0908052A2 (pt) * 2008-02-06 2015-08-11 Wockhardt Research Center Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
CN102149672A (zh) 2008-05-20 2011-08-10 纽罗吉斯克斯公司 水溶性对乙酰氨基酚类似物
DK3192500T3 (da) 2009-05-19 2020-12-21 Neuroderm Ltd Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
NZ601747A (en) 2009-11-09 2014-08-29 Xenoport Inc Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8937151B2 (en) 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
EP2640358B1 (en) 2010-11-15 2018-01-03 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
DK2647619T3 (en) 2010-12-02 2015-03-02 Ono Pharmaceutical Co NEW RELATIONSHIP AND MEDICAL USE THEREOF
JP2014508113A (ja) 2010-12-10 2014-04-03 シンアジャイル コーポレーション 皮下注入可能なレボドパプロドラッグ組成物及び注入方法
WO2012158527A2 (en) * 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
DK2968218T3 (da) 2013-03-13 2021-09-20 Neuroderm Ltd Kombination til behandling af parkinsons sygdom
EP2994453A4 (en) 2013-03-15 2017-04-12 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
SI3209302T1 (sl) 2014-10-21 2019-06-28 Abb Vie Inc. Predzdravila karbidope in L-dope in njihova uporaba za zdravljenje parkinsonove bolezni
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
US20190224220A1 (en) 2016-04-20 2019-07-25 Abbvie Inc. Carbidopa and L-Dopa Prodrugs and Methods of Use
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
KR20240113982A (ko) 2024-07-23
TW202131931A (zh) 2021-09-01
JP6932227B2 (ja) 2021-09-08
KR20230066484A (ko) 2023-05-15
ES2739536T3 (es) 2020-01-31
DK3209302T3 (da) 2019-05-13
BR112017008198A2 (pt) 2017-12-26
FR23C1035I1 (fr) 2023-12-08
US20220153765A1 (en) 2022-05-19
HRP20191285T1 (hr) 2019-10-18
UA120437C2 (uk) 2019-12-10
JP2019218356A (ja) 2019-12-26
JP7688087B2 (ja) 2025-06-03
MX2021003840A (es) 2022-06-30
AU2021201414B2 (en) 2023-05-11
JP2023174770A (ja) 2023-12-08
EP3209302B1 (en) 2019-04-24
US11091507B2 (en) 2021-08-17
LT3209302T (lt) 2019-06-10
JP6567049B2 (ja) 2019-08-28
KR20170071599A (ko) 2017-06-23
IL268885B (en) 2020-08-31
US20180079762A1 (en) 2018-03-22
LUC00304I2 (enExample) 2025-09-22
CN107206013A (zh) 2017-09-26
CN111454290A (zh) 2020-07-28
RS58972B1 (sr) 2019-08-30
RU2021103000A (ru) 2021-03-01
FIC20230014I1 (fi) 2023-03-31
IL251829B (en) 2019-09-26
CA2965379A1 (en) 2016-04-28
SG11201703170RA (en) 2017-05-30
NL301224I2 (nl) 2023-08-16
IL276493A (en) 2020-09-30
HUE044115T2 (hu) 2019-10-28
FR23C1035I2 (fr) 2025-04-18
US20190375770A1 (en) 2019-12-12
EP3569587A1 (en) 2019-11-20
US20230106081A1 (en) 2023-04-06
JP6750076B2 (ja) 2020-09-02
LTPA2023519I1 (enExample) 2023-06-26
RU2743347C2 (ru) 2021-02-17
MY189519A (en) 2022-02-16
CN111494395A (zh) 2020-08-07
TW201630924A (zh) 2016-09-01
JP2025118978A (ja) 2025-08-13
PH12017500746A1 (en) 2017-10-30
US20160106765A1 (en) 2016-04-21
NO2023013I1 (no) 2023-03-20
JP2020189864A (ja) 2020-11-26
IL251829A0 (en) 2017-06-29
NZ769153A (en) 2024-04-26
CN111362980B (zh) 2022-10-18
MX2017005236A (es) 2017-07-26
TR201908296T4 (tr) 2019-06-21
CN111362980A (zh) 2020-07-03
US20200262852A1 (en) 2020-08-20
RU2017117413A3 (enExample) 2019-05-30
JP2021183628A (ja) 2021-12-02
US10174061B2 (en) 2019-01-08
SA521421115B1 (ar) 2022-03-01
SI3209302T1 (sl) 2019-06-28
NL301224I1 (enExample) 2023-03-29
AU2015335941B2 (en) 2021-04-01
CY1121826T1 (el) 2020-07-31
US10730895B2 (en) 2020-08-04
JP2017537066A (ja) 2017-12-14
MX393568B (es) 2025-03-24
TWI718999B (zh) 2021-02-21
US20160362431A1 (en) 2016-12-15
US9446059B2 (en) 2016-09-20
RU2017117413A (ru) 2018-11-26
CY2023010I1 (el) 2023-06-09
AU2021201414A1 (en) 2021-03-25
PT3209302T (pt) 2019-07-19
HUS2300009I1 (hu) 2023-03-28
TWI755257B (zh) 2022-02-11
PH12017500746B1 (en) 2021-12-15
LTC3209302I2 (enExample) 2025-10-10
CY2023010I2 (el) 2023-06-09
EP3209302A1 (en) 2017-08-30
ZA201702760B (en) 2022-05-25
WO2016065019A1 (en) 2016-04-28
IL268885A (en) 2019-10-31
KR102537018B1 (ko) 2023-05-30
SMT201900376T1 (it) 2019-09-09
PL3209302T3 (pl) 2019-10-31
BR112017008198B1 (pt) 2021-02-09
EP4186510A1 (en) 2023-05-31
AU2015335941A1 (en) 2017-05-04
NZ730996A (en) 2024-04-26
AU2025238004A1 (en) 2025-10-16
AR102389A1 (es) 2017-02-22
CN111454290B (zh) 2022-12-23
CN111494395B (zh) 2024-06-21
AU2023210650A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
WO2017184871A9 (en) Carbidopa and l-dopa prodrugs and methods of use
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
MX384262B (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso
BR112019007214A2 (pt) composições do apilimode e métodos para uso do mesmo no tratamento do mal de alzheimer
BR112018077112A2 (pt) uso de liso-gb1 como alvo capaz de ser modulado por um fármaco
UA112489C2 (uk) Спосіб лікування вугрової хвороби шкіри обличчя та спини за індріксоном
AR109154A1 (es) Tratamiento y prevención de los trastornos del sueño, composición farmacéutica, compuesto
AR103448A1 (es) Gel intestinal de levodopa y carbidopa y métodos de uso